Literature DB >> 8507717

Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics.

P P Brons1, C Haanen, J B Boezeman, P Muus, R S Holdrinet, A H Pennings, H M Wessels, T de Witte.   

Abstract

In a prospective study of 33 newly diagnosed patients with acute myeloid leukemia (AML), we analyzed the relationship of proliferation parameters with clinical parameters, response to induction therapy, and survival. The median follow-up was 26 months. The proliferative capacity of the leukemic progenitor cells was studied using colony-forming assays (number of colony-forming units, growth pattern, and spontaneous clonogenic growth capacity). The cell kinetic parameters of the bone marrow blasts were determined by in vivo labeling with iododeoxyuridine and subsequent flow cytometry: labeling index (LI), DNA synthesis time (Ts), potential doubling time. No or only weak relationships were observed between the experimental and clinical parameters such as age, sex, % blasts, white blood cell count, FAB subtype, cytogenetics, and % CD 34+ cells. This suggests that clonogenic growth and cell cycle kinetics of bone marrow blasts are independent cell biologic properties of AML. No association between the proliferation parameters and induction response rate was noticed. Analysis of the overall survival and event-free survival revealed trends to longer survival rates in patients with a below-median LI (< or = 7.6%) and below-median Ts value (< or = 14.3 h). These trends were more pronounced in the group of de novo AML (n = 23), where the prolonged event-free survival in patients with below-median Ts reached statistical significance (p = 0.02). None of the other parameters appeared significantly correlated with survival, although there was a trend to longer survival rates in patients who had no spontaneous clonogenic growth capacity (p = 0.13). In conclusion, proliferation parameters in leukemic cells provide additional information on the cell biologic characteristics of AML, and these parameters may have prognostic value for response and duration of survival in AML.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507717     DOI: 10.1007/BF01738470

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  49 in total

1.  Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow.

Authors:  C I Civin; M L Banquerigo; L C Strauss; M R Loken
Journal:  Exp Hematol       Date:  1987-01       Impact factor: 3.084

2.  A rapid flow cytometric method for bivariate bromodeoxyuridine/DNA analysis using simultaneous proteolytic enzyme digestion and acid denaturation.

Authors:  P E van Erp; P P Brons; J B Boezeman; G J de Jongh; F W Bauer
Journal:  Cytometry       Date:  1988-11

3.  Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.

Authors:  N Van Der Lely; T De Witte; P Muus; R Raymakers; F Preijers; C Haanen
Journal:  Exp Hematol       Date:  1991-05       Impact factor: 3.084

4.  Interaction of iododeoxyuridine and its primary metabolite, iodouracil on radiation response.

Authors:  T J Kinsella; P P Dobson; J B Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

5.  Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation.

Authors:  T de Witte; R Raymakers; A Plas; E Koekman; H Wessels; C Haanen
Journal:  Transplantation       Date:  1984-02       Impact factor: 4.939

6.  Deoxyribonucleic acid synthesis time of erythropoietic and granulopoietic cells in human beings.

Authors:  P Stryckmans; E P Cronkite; J Fache; T M Fliedner; J Ramos
Journal:  Nature       Date:  1966-08-13       Impact factor: 49.962

7.  Rescue from programmed cell death in leukemic and normal myeloid cells.

Authors:  J Lotem; E J Cragoe; L Sachs
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

8.  Bone-marrow-profileration patterns in acute myeloblastic leukaemia determined by pulse cytophotometry.

Authors:  H Hillen; J Wessels; C Haanen
Journal:  Lancet       Date:  1975-03-15       Impact factor: 79.321

9.  Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia.

Authors:  A Riccardi; M Giordano; M Danova; M Girino; S Brugnatelli; G Ucci; G Mazzini
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Factors influencing prognosis in adults with acute myelogenous leukaemia.

Authors:  D Crowther; M E Beard; C J Bateman; R L Sewell
Journal:  Br J Cancer       Date:  1975-10       Impact factor: 7.640

View more
  5 in total

1.  Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time.

Authors:  P P Brons; N Van der Lely; C Haanen; A H Pennings; J B Boezeman; J M Wessels; R A Raijmakers; T J de Witte
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

Review 2.  Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.

Authors:  Zbigniew Darzynkiewicz; Frank Traganos; Donald Wlodkowic
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

3.  In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

Authors:  N Van der Lely; T De Witte; J Wessels; R Raymakers; P Muus; F Preijers
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

Review 4.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

5.  In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment.

Authors:  Jan Christoph Banck; Dennis Görlich
Journal:  BMC Syst Biol       Date:  2019-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.